BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 36634747)

  • 1. Genomic landscape of Chinese patients with hepatocellular carcinoma using next-generation sequencing and its association with the prognosis.
    Yang Z; Liu J; Xue F; Zhang L; Xue H; Wu Y; Bai S; Du F; Wang X; Deng W; Song C; Wang K
    Ann Hepatol; 2023; 28(2):100898. PubMed ID: 36634747
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genomic profiling of combined hepatocellular-cholangiocarcinoma reveals similar genetics to hepatocellular carcinoma.
    Joseph NM; Tsokos CG; Umetsu SE; Shain AH; Kelley RK; Onodera C; Bowman S; Talevich E; Ferrell LD; Kakar S; Krings G
    J Pathol; 2019 Jun; 248(2):164-178. PubMed ID: 30690729
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mutation profile and its correlation with clinicopathology in Chinese hepatocellular carcinoma patients.
    Wang S; Shi H; Liu T; Li M; Zhou S; Qiu X; Wang Z; Hu W; Guo W; Chen X; Guo H; Shi X; Shi J; Zang Y; Cao J; Wu L
    Hepatobiliary Surg Nutr; 2021 Apr; 10(2):172-179. PubMed ID: 33898558
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genomic sequencing identifies WNK2 as a driver in hepatocellular carcinoma and a risk factor for early recurrence.
    Zhou SL; Zhou ZJ; Hu ZQ; Song CL; Luo YJ; Luo CB; Xin HY; Yang XR; Shi YH; Wang Z; Huang XW; Cao Y; Fan J; Zhou J
    J Hepatol; 2019 Dec; 71(6):1152-1163. PubMed ID: 31349001
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comprehensive analyses of mutations and hepatitis B virus integration in hepatocellular carcinoma with clinicopathological features.
    Kawai-Kitahata F; Asahina Y; Tanaka S; Kakinuma S; Murakawa M; Nitta S; Watanabe T; Otani S; Taniguchi M; Goto F; Nagata H; Kaneko S; Tasaka-Fujita M; Nishimura-Sakurai Y; Azuma S; Itsui Y; Nakagawa M; Tanabe M; Takano S; Fukasawa M; Sakamoto M; Maekawa S; Enomoto N; Watanabe M
    J Gastroenterol; 2016 May; 51(5):473-86. PubMed ID: 26553052
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeted Molecular Profiling of Circulating Cell-Free DNA in Patients With Advanced Hepatocellular Carcinoma.
    Cowzer D; White JB; Chou JF; Chen PJ; Kim TH; Khalil DN; El Dika IH; Columna K; Yaqubie A; Light JS; Shia J; Yarmohammadi H; Erinjeri JP; Wei AC; Jarnagin W; Do RKG; Solit DB; Capanu M; Shah RH; Berger MF; Abou-Alfa GK; Harding JJ
    JCO Precis Oncol; 2023 Sep; 7():e2300272. PubMed ID: 37769223
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Next generation sequencing reveals genetic landscape of hepatocellular carcinomas.
    Li S; Mao M
    Cancer Lett; 2013 Nov; 340(2):247-53. PubMed ID: 23063663
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical Impact of Genomic Diversity From Early to Advanced Hepatocellular Carcinoma.
    Nault JC; Martin Y; Caruso S; Hirsch TZ; Bayard Q; Calderaro J; Charpy C; Copie-Bergman C; Ziol M; Bioulac-Sage P; Couchy G; Blanc JF; Nahon P; Amaddeo G; Ganne-Carrie N; Morcrette G; Chiche L; Duvoux C; Faivre S; Laurent A; Imbeaud S; Rebouissou S; Llovet JM; Seror O; Letouzé E; Zucman-Rossi J
    Hepatology; 2020 Jan; 71(1):164-182. PubMed ID: 31206197
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular characterization-based multi-omics analyses in primary liver cancer using the Japanese version of the genome atlas.
    Imamura T; Okamura Y; Ohshima K; Uesaka K; Sugiura T; Yamamoto Y; Ashida R; Ohgi K; Nagashima T; Yamaguchi K
    J Hepatobiliary Pancreat Sci; 2023 Mar; 30(3):269-282. PubMed ID: 35918906
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Target genes discovery through copy number alteration analysis in human hepatocellular carcinoma.
    Gu DL; Chen YH; Shih JH; Lin CH; Jou YS; Chen CF
    World J Gastroenterol; 2013 Dec; 19(47):8873-9. PubMed ID: 24379610
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeted Next-Generation Sequencing Combined With Circulating-Free DNA Deciphers Spatial Heterogeneity of Resected Multifocal Hepatocellular Carcinoma.
    Lin J; Zhao S; Wang D; Song Y; Che Y; Yang X; Mao J; Xie F; Long J; Bai Y; Yang X; Zhang L; Bian J; Lu X; Sang X; Pan J; Wang K; Zhao H
    Front Immunol; 2021; 12():673248. PubMed ID: 34211467
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TERT promoter mutations and chromosome 8p loss are characteristic of nonalcoholic fatty liver disease-related hepatocellular carcinoma.
    Ki Kim S; Ueda Y; Hatano E; Kakiuchi N; Takeda H; Goto T; Shimizu T; Yoshida K; Ikura Y; Shiraishi Y; Chiba K; Tanaka H; Miyano S; Uemoto S; Chiba T; Ogawa S; Marusawa H
    Int J Cancer; 2016 Dec; 139(11):2512-8. PubMed ID: 27511114
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of novel therapeutic targets in the PI3K/AKT/mTOR pathway in hepatocellular carcinoma using targeted next generation sequencing.
    Janku F; Kaseb AO; Tsimberidou AM; Wolff RA; Kurzrock R
    Oncotarget; 2014 May; 5(10):3012-22. PubMed ID: 24931142
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Histological subtypes of hepatocellular carcinoma are related to gene mutations and molecular tumour classification.
    Calderaro J; Couchy G; Imbeaud S; Amaddeo G; Letouzé E; Blanc JF; Laurent C; Hajji Y; Azoulay D; Bioulac-Sage P; Nault JC; Zucman-Rossi J
    J Hepatol; 2017 Oct; 67(4):727-738. PubMed ID: 28532995
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TP53 and RET may serve as biomarkers of prognostic evaluation and targeted therapy in hepatocellular carcinoma.
    Ye S; Zhao XY; Hu XG; Li T; Xu QR; Yang HM; Huang DS; Yang L
    Oncol Rep; 2017 Apr; 37(4):2215-2226. PubMed ID: 28350084
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comprehensive analysis of genetic aberrations linked to tumorigenesis in regenerative nodules of liver cirrhosis.
    Kim SK; Takeda H; Takai A; Matsumoto T; Kakiuchi N; Yokoyama A; Yoshida K; Kaido T; Uemoto S; Minamiguchi S; Haga H; Shiraishi Y; Miyano S; Seno H; Ogawa S; Marusawa H
    J Gastroenterol; 2019 Jul; 54(7):628-640. PubMed ID: 30756187
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Accumulation of Molecular Aberrations Distinctive to Hepatocellular Carcinoma Progression.
    Midorikawa Y; Yamamoto S; Tatsuno K; Renard-Guillet C; Tsuji S; Hayashi A; Ueda H; Fukuda S; Fujita T; Katoh H; Ishikawa S; Covington KR; Creighton CJ; Sugitani M; Wheeler DA; Shibata T; Nagae G; Takayama T; Aburatani H
    Cancer Res; 2020 Sep; 80(18):3810-3819. PubMed ID: 32641413
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of TP53 mutations with stem cell-like gene expression and survival of patients with hepatocellular carcinoma.
    Woo HG; Wang XW; Budhu A; Kim YH; Kwon SM; Tang ZY; Sun Z; Harris CC; Thorgeirsson SS
    Gastroenterology; 2011 Mar; 140(3):1063-70. PubMed ID: 21094160
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The genomic landscape of hepatoblastoma and their progenies with HCC-like features.
    Eichenmüller M; Trippel F; Kreuder M; Beck A; Schwarzmayr T; Häberle B; Cairo S; Leuschner I; von Schweinitz D; Strom TM; Kappler R
    J Hepatol; 2014 Dec; 61(6):1312-20. PubMed ID: 25135868
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Applications of next-generation sequencing analysis for the detection of hepatocellular carcinoma-associated hepatitis B virus mutations.
    Wu IC; Liu WC; Chang TT
    J Biomed Sci; 2018 Jun; 25(1):51. PubMed ID: 29859540
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.